投资近20亿元，武汉将建首个国家一类创新药生产基地

Group 1 - A significant number of innovative drug projects have accelerated their establishment in the East Lake High-tech Zone, with Shenzhen Fowo Pharmaceutical Co., Ltd. investing nearly 2 billion yuan to build its headquarters and an innovative drug R&D, production, and sales base in Wuhan, marking the city's first national class innovative drug production base [1][2] - Fowo Pharmaceutical is a national high-tech enterprise focused on the R&D of next-generation small molecule innovative anti-tumor drugs, with a product matrix that includes over 10 national class innovative drugs, including two core products targeting lung cancer and breast cancer, which have a leading advantage in China [2] - The company plans to construct a 20,000 square meter facility in two phases, with the first phase covering 2,000 square meters, including 1,000 square meters for office space and another 1,000 square meters for the R&D base, which is expected to be completed and put into use this year [2][5] Group 2 - The innovative drug FWD1802, developed for breast cancer treatment, has recently received approval from the National Medical Products Administration of China to enter clinical trials, with expectations for domestic market launch by 2026 [5] - The East Lake High-tech Zone is committed to focusing on the life and health industry, supporting major scientific research projects and key investment projects to create a cluster for innovative drug and high-end medical device R&D and production [8] - The local government has released policies to support the development of innovative drugs targeting major diseases such as cancer and cardiovascular diseases, aiming to cultivate 20 innovative drug companies and launch 30 national class new drugs by 2030 [8]